{"classes":[{"categories":[{"measurements":[{"comment":"The median overall survival with censoring for transplant has not been reached","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"The median overall survival with censoring for transplant has not been reached","groupId":"OG001","lowerLimit":"27.4","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"360"},{"groupId":"OG001","value":"357"}],"units":"Participants"}],"description":"Overall survival (OS) was defined as the time interval from randomization to death from any cause. Any participants who received a stem cell transplant were censored at the time of transplant. The median OS with 95% CI was estimated using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients will receive daunorubicin 60 mg/m\\^2 by IV push days 1-3 plus cytarabine 200 mg/m\\^2 IV days 1-7, and midostaurin 50 mg orally twice daily days 8-21. Participants achieving remission will receive four 28 day cycles of high dose cytarabine (3000 mg/m\\^2) days 1, 3, \\& 5 and midostaurin at 50 mg orally twice daily days 8-14. Maintenance therapy was given to participants who continued in remission for 12 28-day cycles of midostaurin 50 mg orally twice daily.","id":"OG000","title":"Induction and Consolidation Chemotherapy Plus Midostaurin"},{"description":"Patients will receive daunorubicin 60 mg/m\\^2 by IV push days 1-3 plus cytarabine 200 mg/m\\^2 IV days 1-7, and placebo 50 mg orally twice daily days 8-21. Participants achieving remission will receive four 28 day cycles of high dose cytarabine (3000 mg/m\\^2) days 1, 3, \\& 5 and placebo at 50 mg orally twice daily days 8-14. Maintenance therapy was given to participants who continued in remission for 12 28-day cycles of placebo 50 mg orally twice daily.","id":"OG001","title":"Induction and Consolidation Chemotherapy Plus Placebo"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Duration of study (Up to 10 years)","title":"Overall Survival, Censoring Participants Who Receive a Stem Cell Transplant at the Time of the Transplant","type":"SECONDARY","unitOfMeasure":"months"}